Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development.

NPJ vaccines·2026
Same author

Volume-based bias in automated measurements of lateral ventricle and hippocampal volumes of mild traumatic brain injury patients.

Neuroimage. Reports·2026
Same author

Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations.

NPJ vaccines·2026
Same author

Large-scale discovery, analysis and design of protein energy landscapes.

Nature·2026
Same author

Junction opener enables CAR T cell treatment of solid tumors.

Scientific reports·2026
Same author

A systematic review of transcranial electrical stimulation and meta-analysis of transcranial direct current stimulation RCTs in unipolar and bipolar depression.

Journal of affective disorders·2026

Related Experiment Video

Updated: Jun 20, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Optimized subunit vaccine protects against experimental leishmaniasis.

Sylvie Bertholet1, Yasuyuki Goto, Lauren Carter

  • 1Infectious Disease Research Institute, Seattle, WA 98104, USA. sbertholet@idri.org

Vaccine
|September 30, 2009
PubMed
Summary

A new subunit vaccine using the Leish-110f antigen showed protective efficacy against Leishmania parasites. Adjuvants like MPL-SE and EM005 enhanced immune responses, including T cell activity, for improved vaccine performance.

More Related Videos

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major
08:17

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Related Experiment Videos

Last Updated: Jun 20, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major
08:17

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Area of Science:

  • Immunology
  • Vaccinology
  • Parasitology

Background:

  • Developing effective vaccines against Leishmania species requires specific antigens and adjuvants to elicit robust immune responses.
  • Previous vaccine generations highlighted the need for improved antigens and adjuvant formulations.

Purpose of the Study:

  • To evaluate the immunogenicity and protective efficacy of a second-generation polyprotein antigen, Leish-110f, combined with novel adjuvant formulations against Leishmania challenges.
  • To assess the immune response profiles, including antibody and T cell activity, induced by the Leish-110f subunit vaccine.

Main Methods:

  • The Leish-110f antigen was formulated with natural (MPL-SE) and synthetic (EM005) Toll-like receptor 4 agonists.
  • Vaccinated animals were challenged with Leishmania parasites to assess protective efficacy.
  • Immune responses, including antibody production and T cell cytokine profiles (IFN-gamma, TNF, IL-2) from CD4+ T cells, were analyzed.

Main Results:

  • The Leish-110f subunit vaccine, when adjuvanted with MPL-SE or EM005, demonstrated significant immunogenicity and protective efficacy against Leishmania challenge.
  • Vaccine-induced protection correlated with robust antibody and T cell responses targeting the Leish-110f antigen.
  • CD4 T cells produced key cytokines such as IFN-gamma, TNF, and IL-2, indicating a strong cellular immune response.

Conclusions:

  • The improved Leish-110f subunit vaccine antigen, when adjuvanted with natural or synthetic Toll-like receptor 4 agonists, is immunogenic and confers protection against Leishmania species.
  • This study validates the potential of Leish-110f as a core component for next-generation Leishmania vaccines.